Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

An open-label, randomized phase II study of Herceptin (trastuzumab), Taxotere (docetaxel) and Xeloda (capecitabine) in combination, versus Herceptin (trastuzumab) plus Taxotere (docetaxel), in patients with advanced and/or metastatic breast cancers that overexpress HER2.
trastuzumab
MO16419
HER2-positive metastatic breast cancer
Phase 2
 
July 2015

Powered by ideaPoint, Inc.